LATE STAGE DEVELOPMENT OF AN PROTEIN-BASED TUMOUR VACCINE FOR RENAL CELL CARCINOMA
VCC MEDICAL DIVISION IS DEVELOPING CLINICALLY PROVEN PRODUCTS, SHOWN TO MAINTAIN REMISSION AND ALLEVIATE DISEASE
VCC-001 cancer vaccine Phase III data in Renal Cell Cancer has
demonstrated clinical effect and was well tolerated, a disease with few current treatment options
VCC-001 cancer vaccine platform has significant potential in metastatic renal cell, colon and pancreatic cancers
Company Details
- Employees
- 6
- Founded
- 2006
- Address
- Gerechtigkeitsgasse, 25,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.vaccentis.com
- Keywords
- Biotechnologie, Onkologie, Tumor Vaccine.
- HQ
- Zürich , Switzerland
Vaccentis Questions
Vaccentis's website is http://www.vaccentis.com
Vaccentis's LinkedIn profile is https://ch.linkedin.com/company/vaccentis-ag
Vaccentis has
6 employees.
View email and phone details for 6
employees at Vaccentis.
Vaccentis's industry is
Biotechnology Research
Vaccentis's top competitors are
Cancerappy,
Elusis,
Canvirex,
Crearene Ag,
Convergence Partners,
Abi,
Prosoma,
Adoram Therapeutics,
Rdp Pharma Ag,
8 Hours Ahead.
Vaccentis's categories are Biotechnology Research
Vaccentis's founding year is 2006
